CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is positioned for growth with multiple gene editing treatments in the pipeline, such as CASGEVY for sickle cell disease and transfusion-dependent beta-thalassemia. Additionally, their strong financial standing, with a recent $600 million note and an estimated $2.56 billion in cash, provides a stable foundation for their research and development efforts. Although there are potential risks in the gene editing field, CRISPR's potential for success and their Overweight rating with a target of $110 make them a promising investment opportunity.

CRISPR Therapeutics is facing clinical and commercial risks in the development of its gene editing therapies, especially in regards to recruitment challenges and safety concerns surrounding off-target mutations. While their first approved drug Casgevy has shown promising results in targeting sickle-cell disease and transfusion-dependent beta-thalassemia, the company's pipeline may face competition and challenges in differentiation. Additionally, the success of CRISPR Therapeutics' gene editing technology may be hindered by the presence of other treatments for these diseases. Despite an increase in Casgevy sales in 2025, there is a possibility that the company may not be able to achieve its goal of $1 billion in global sales by 2030. Therefore, based on a probability-adjusted DCF analysis and a sum-of-the-parts analysis, our $82 price target and Buy rating are maintained, but it should be noted that there is a potential for increased dilution and decreased pipeline value due to at-the-market financing.